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Factors influencing PCV13 specific 
antibody response in Danish 
children starting in day care
Sine fjeldhøj1,5, Eva fuglsang2,5, Camilla Adler Sørensen1, Hanne frøkiær  2, 
Karen Angeliki Krogfelt  1,3, Rikke Pilmann Laursen4 & Hans-Christian Slotved  1*
This study examines different factors influencing the 13-valent pneumococcal conjugate vaccine 
(PCV13) specific antibody response in 8–13 months old Danish children starting in day care. We present 
secondary findings to the ProbiComp study, which included nose swabs, buccal swabs and blood 
samples from the children before entering day care (baseline) and again after 6 months. Pneumococci 
isolated from nose swabs were identified by latex agglutination kit and Quellung reaction. Luminex-
based assay was used for antibody measurements against specific anti-pneumococcal capsular IgG. 
Buccal gene expression was analyzed by qPCR. Statistical analyses were performed in R and included 
Pearson’s Chi-squared test, Welch two sample t-test and linear regression models. The PCV13 antibody 
response was unaffected by whether the children were carriers or non-carriers of any pneumococcal 
serotype. Having siblings increased the risk of carrying serotype 21 before day care (p = 0.020), and 
having siblings increased the PCV13 antibody response at the end of study (p = 0.0135). Hepatitis 
B-vaccination increased the PCV13 antibody response before day care attendance (p = 0.005). The 
expression of IL8 and IL1B was higher in children carrying any pneumococcal serotype at baseline 
compared to non-carriers (p = 0.0125 and p = 0.0268 respectively).
Invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae (S. pneumoniae) is associated with 
high mortality and morbidity worldwide, especially among elderly aged 65+ years old and young children <2 
years of age1. More than 92 different serotypes of S. pneumoniae are known2 and the 13-valent pneumococcal 
conjugate vaccine (PCV13), which was introduced into the Danish Childhood Immunization Program in 2010, 
protects against 13 of the known serotypes (serotype 1, 3, 4, 5, 6 A, 6B, 7 F, 9 V, 14, 18 C, 19 A, 19 F and 23 F)1,3. The 
use of effective pneumococcal conjugate vaccines in children led among all ages to a significant reduction in IPD 
caused by serotypes included in the vaccines, especially among children <2 years of age and elderly aged 65+ 
years old1,4–7. The PCV13 elicits antibody responses against the vaccine-included serotypes and thereby protects 
against vaccine serotypes8. Carriage of S. pneumoniae is most frequent in children <5 years of age, markedly in 
children <2 years of age, and pneumococcal carriage is a prerequisite for developing IPD9,10. Furthermore, a high 
carriage rate is associated with a high risk of respiratory infections11.
Children attending day care have an increased risk of pneumococcal carriage10,12–14 and a higher incidence 
of respiratory infections and hospitalizations due to acute respiratory infections compared to children in home 
care15,16. Around 90% of all Danish children aged one to two years old attend day care (Statistics Denmark, https://
www.dst.dk/en, access 30-03-2020), hence it is important to examine strategies to reduce or prevent infections 
in children attending day care. The implementation of effective pneumococcal vaccines led to an increase in 
carriage of non-vaccine serotypes and an increase in the incidence of IPD caused by non-vaccine serotypes1,3,5,10. 
S. pneumoniae is known for capsular switching17. Thus, it is of great importance to continue the surveillance of 
pneumococcal carriage and to monitor the effect of pneumococcal vaccination on non-vaccine serotype carriage 
and subsequent development of diseases associated with S. pneumoniae.
The purpose of this study was to identify possible correlations between carriage of pneumococcal serotypes in 
PCV13-vaccinated children and the production of serotype-specific antibodies in children.
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Methods
Design and study population. This study presents secondary findings of the children included in the 
ProbiComp study18, which investigated the effect of a daily oral administration of a combination of the probiotics 
Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis subsp lactis (BB-12) for six months to children 
aged 8–13 months at the time of day care enrolment. LGG and BB-12 are registered trademarks of Chr. Hansen 
A/S. The ProbiComp study was a randomized, double-blind, placebo-controlled parallel study which examined 
whether the probiotics influenced infections in young children and is described in details in Laursen et al.18. 
Figure 1 shows a modified flowchart of participants and obtained sample numbers per method as presented in 
Laursen et al.18.
Briefly, 290 healthy children aged 8–13 months starting day care within 12 weeks after start of intervention 
were included in the study. Recruitment was done over two seasons from mid-August to mid-December in 2014 
and 2015. The children were clinically examined at two visits; one visit at baseline before starting in day care and 
one visit 6 months later at the end of study18.
At baseline and at the end of study nose and buccal swabs and a blood sample were drawn from the chil-
dren and the carrier status and PCV13 geometric mean antibody response were analyzed by serotyping by a 
Luminex-based assay respectively.
Table 1 shows characteristics of study participants with nasal and oral swab samples from baseline and from 
the end of study. Data from the probiotic group and placebo group is combined as one group for this study. The 
table includes gender, siblings, breastfeeding prevalence, indoor pets, iron supplementation, health status since 
birth, age, vaccination (PCV13 and HepB coverage) and compliance (Table 1). Partial data in Table 1 has been 
presented in Laursen et al.18.
Vaccination data of the study population. Vaccination data were obtained at the Danish Vaccination Register 
(DDV) (record number 2015-57-0102). The vaccination data were used to assess the time between last given 
vaccination and blood sampling time. The data include information regarding which vaccines the specific child 
had received and date of vaccination. PCV13 is administered at the age of 3 months, 5 months and 12 months in 
a 2 + 1 dose schedule in Denmark1. At baseline, almost all the examined children (98.2%) were covered by at least 
one dose of PCV13, while 92.6% were covered by two doses. At the end of intervention 88.0% of the children had 
received all three doses of PCV13. Children with no vaccination data registered (n = 6) were excluded for analyses 
regarding vaccination status.
All children participating in the study have followed the Danish childhood vaccination program 
(except the aforementioned 6 children with no vaccination data registered). (https://en.ssi.dk/vaccination/
the-danish-childhood-vaccination-programme, access 30-03-2020). In Denmark, hepatitis B vaccination is not 
included in the Danish childhood vaccination program but mainly recommended for people who are travelling 
outside of Denmark (https://en.ssi.dk/vaccination/travel-vaccination, access 30-03-2020). Almost half of the chil-
dren were additionally covered by hepatitis B vaccination (137 children at baseline and 152 children at the end 
of study).
Nasal swab sampling. Nasal swab samples were collected by a modified version of Satzke et al.19 and were used to 
investigate carriage of S. pneumoniae. Briefly, minitip flocked swabs (FLOQSwabsTM, Copan, Italy) were inserted 
Figure 1. Flowchart of participants and obtained sample numbers per method.
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into the nasal cavity as far as possible but limited due to the child’s comfort. The swabs were placed in 1 mL 
Luria-Bertani (LB) broth with 10% glycerol in cryotubes and stored at −80 °C until analysis.
Identification of pneumococcal serotypes. The identification of pneumococcal serotypes was performed as pre-
viously described9,10 Briefly, inoculated serum-ox broth was incubated overnight at 37 °C in 5% CO2 before plat-
ing on 10% horse blood agar plates to increase sensitivity9. Pneumococcal serotypes were identified based on 
optochin sensitivity, bile solubility, α-hemolysis, pneumotest latex agglutination kit (SSI Diagnostica, Hillerød, 
Denmark) performed on the serum-broth and Quellung reaction (Neufeld test) using serotype specific antisera 
(SSI Diagnostica, Hillerød, Denmark). The specimens were screened by pneumotest latex agglutination kit for 
multiple serotypes. If multiple serotypes were found, they were isolated and serotyped.
Blood sampling and sample preparation. The peripheral whole blood was drawn at baseline and at the 
end of intervention as previously described8. Aliquots (approximately 0.5 mL) were subsequently sampled accord-
ing to the type of analysis and serum was collected and stored at −80 °C until examination by LuminexA. It was 
possible to collect blood samples from 252 children at baseline and 231 children at the end of study, however the 
analyses were limited by the aliquot volume of the collected blood, which was not always sufficient. The number 
of blood samples, nasal swabs and buccal swabs included for analyses is listed in flowchart 1.
Antibody measurements of S. pneumoniae serotypes. The PCV13 geometric mean antibody 
responses were analyzed by a Luminex-based assay.
Luminex-based assay was used for antibody measurements against specific anti-pneumococcal capsular IgG 
(IgG-PN) as described by Kantsø et al.20. The assay was performed for 12 S. pneumoniae serotypes (1, 3, 4, 5, 6B, 
7 F, 9 V, 14, 18 C, 19 A, 19 F and 23 F) since it was not possible to measure more than those serotypes with our 
current technology.
Interleukin gene expression. Buccal gene expression was analyzed by qPCR. The collection of buccal 
swabs and measurement of gene expression by RT-qPCR was done as described in Hauger et al.21. In brief, the 
buccal swabs were collected by gently scraping the child’s inner cheek with a 0.6 mm interdental brush (TePe), 
which was immersed in isopropanol and lysis binding solution (MagMAX) after sampling and stored at −20 °C.
RNA was extracted with the MagMAX-96 Total RNA Isolation kit, and complementary DNA synthesized with 
the High Capacity with a total reaction volume of 10 μL consisting of 2 μL cDNA, 20 µL TaqMan gene expression 
assay and 2 µL TaqMan Fast Universal PCR Mastermix. cDNA Reverse Transcriptase kit (Applied Biosystems). 
Gene expression analysis was performed by qPCR on the StepOne instrument with universal fast thermal cycling 
parameters (ThermoFischer Scientific) on 2 μL cDNA, corresponding to 2.5 ng of RNA, in a total volume of 10 μL 
as previously described21.
Each sample was amplified in duplicates and the mean used in the analysis. The expression of interleukin (IL)8 
(IL8: Hs00174103_m1) and IL1B (IL1B: Hs01555410_m1 was measured, and Beta-actin (ACTB: Hs01060665_g1) 
Parameter Total
Probiotic group, n (%) 132 (50.0)
Female, n (%) 129 (48.9)
Siblings, n (%) 134 (50.8)
Breastfeeding prevalence:
1st visit, n (%) 127 (48.1)
2nd visit, n (%) 25 (9.5)
Indoor pets, n (%) 55 (20.8)
Iron supplementation, n (%) 95 (36.0)
Health status since birth:
Doctor-diagnosed otitis media, n (%) 78 (29.5)
Doctor-diagnosed bronchitis, n (%) 23 (8.7)
Doctor-diagnosed pneumonia, n (%) 27 (10.2)
Oral/systemic antibiotic treatment 98 (37.1)
Age:
1st visit (median months, IQR) 9.9 (9.5–10.4)
Start daycare (median months, IQR) 10.4 (9.9–11.2)
2nd visit (median months, IQR) 16.1 (15.6–16.6)
Vaccination:
PCV-13 coverage ≤ 1 at visit 1, n (%) 264 (100.0)
HepB coverage ≤ 1 at visit 1, n (%) 122 (46.2)
HepB coverage ≤ 1 at visit 2, n (%) 136 (51.5)
Compliance:
2nd visit (median % of consumed stics, IQR) 97 (94–99)
Table 1. Characteristics of study participants (n = 264).
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was used as reference gene. Change in gene expression was calculated by the relative quantification cycle 
(Cq) method (2-ΔΔCq), where expression of each target gene was normalized to ACTB as ΔCq = Cq(target) 
- Cq(reference).
Statistics. Baseline characteristics are shown as the mean (SD) or median (interquartile range [IQR]) for 
continuous variables and n (%) for categorical variables. Only children with nasal swabs, blood samples, or buccal 
swabs available for both visits were included in the analyses of carrier status, PCV13 vaccine response, or gene 
expression respectively. Differences according to having siblings, being vaccinated against hepatitis B, besides 
the Danish basic vaccination program, or being a nasal carrier or not were analyzed by linear regression models. 
For some analysis, a multivariate analysis was done to adjust for siblings as a potential confounder. All statistical 
analyses were performed in the software R (version 3.4.3; R Core Team, 2017. R: a language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria). An estimate was considered 
statistically significant at p < 0.05.
Ethical considerations. The ProbiComp study protocol was approved by the Committees on Biomedical 
Research Ethics for the Capital Region of Denmark (H-4-2014-032). All methods were performed according 
to the guidelines and regulations approved by the Committees on Biomedical Research Ethics. Furthermore, 
the study was registered at clinicaltrials.gov (identifier NCT02180581, posted 02/07/2014)18. The study required 
informed consent from parents or other legal guardians of the children. Participation in the study was voluntary 
and parents could withdraw their consent at any time18.
Results
Previous studies show no statistical significance between the probiotics group and the placebo group when com-
paring carriage rate of pneumococcal serotypes and no significant difference in antibody response to PCV138,10. 
Furthermore, no significant differences between the groups were seen in terms of gender, siblings, breastfeeding, 
indoor pets, health status since birth, smoking in the household, age or compliance18, thus the two groups were 
compiled for analyses in this study (Table 1).
There was no statistically significant difference in antibody response to PCV13 vaccination when comparing 
carriers and non-carriers at baseline (p = 0.147) nor at the end of study (p = 0.942), (Fig. 2).
The PCV13 antibody response in children carrying 0, 1, or 2 pneumococcal strains was assessed. We found 
that the antibody response increased slightly with increasing number of strains carried at baseline, but tended 
to decrease with increasing number of strains carried at the end of study, yet neither the increase at baseline 
(p = 0.122) or the decrease at the end of study (p = 0.996) were considered significant (Fig. 3).
In a previous study10 we found that children living with siblings had a significant higher carriage rate of S. 
pneumoniae compared to only children. In this study, we assessed the PCV13 antibody response in children with 
and without siblings as novel information and found that at baseline there was no significant statistical difference 
in the PCV13 antibody response when compared children with and without siblings (p = 0.157), but having sib-
lings increased the PCV13 antibody response (µg/mL) at the end of study (p = 0.0135) (Fig. 4).
The antibody response to PCV13 in children who received all vaccines included in the Danish childhood 
vaccination program and children who further received the hepatitis B-vaccination were compared in Fig. 5. 
Being vaccinated against hepatitis B in addition to the Danish childhood vaccination program increased the 
PCV13 antibody response at baseline (p = 0.005) but not at the end of study (p = 0.474) in children <2 years 
of age. Multivariate analysis adjusting for number of siblings showed that hepatitis B-vaccination significantly 
increased the PCV13 antibody response at baseline (p = 0.009) while the number of siblings had no impact on 
the PCV13 antibody response at baseline (p = 0.142). At the end of study hepatitis B-vaccination did not impact 
Figure 2. Antibody response to PCV13 and carriage of pneumococcal serotypes at baseline and at the end of 
study.
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the PCV13 antibody response when adjusting for siblings (p = 0.468), but the number of siblings did have a sig-
nificant impact (p = 0.019).
Buccal gene expressions of IL8 and IL1B in children that were carriers of pneumococcal serotypes and 
non-carriers were tested (Fig. 6). The expression of IL-8 and IL-1B was higher in children who carried any sero-
type in the nose at baseline compared to non-carriers, but not at the end of study. Multivariate analysis was 
performed to examine whether the number siblings impacted the correlation between buccal gene expression 
of IL8 and IL1B and carrier status of pneumococcal serotypes. Being a carrier of S. pneumoniae significantly 
increased the gene expression of IL8 (p = 0.044) and IL1B (p = 0.038) at baseline when adjusting for number of 
siblings. Though at the end of study neither the number of siblings (p = 0.995) nor being a carrier of S. pneumo-
niae (p = 0.772) had an impact on IL8 expression or IL1B expression (p = 0.778 and p = 0.848 for siblings and 
carrier status, respectively), when performing multivariate analysis.
The antibody response to specific serotypes depending on the carriage of specific serotypes is included as a 
supplementary figure. E.g. the antibody response to serotype 19 F was lower in children carrying serotype 23B 
compared to children not carrying serotype 23B (p = 0.0453), although the number of children carrying 23B was 
small (four carriers compared to 156 non-carriers) making the results questionable. For the majority of the sero-
types it was not possible to calculate differences in antibody responses in children carrying specific serotypes or 
not due to low numbers of children being carriers compared to non-carriers (supplementary figure 1).
Discussion
As a secondary finding of the ProbiComp study, we have assessed the association between the PCV13 antibody 
response and the carriage status of S. pneumoniae serotypes in healthy children aged 8–13 months starting in day 
care. It was previously shown that daily administration of a combination of Bifidobacterium animalis ssp. lactis 
and Lactobacillus rhamnosus GG for a 6-month intervention period did not affect the antibody response against 
S. pneumoniae in healthy Danish children in terms of geometric mean of the antibody concentrations against 12 S. 
Figure 3. Antibody response to PCV13 and number of strains carried at baseline and at the end of study.
Figure 4. Antibody response to PCV13 (µg/mL) in children with or without siblings at baseline and end of 
study (no siblings, n = 81; siblings, n = 79). Having siblings increases the PCV13 antibody response at the end 
of study. At baseline and end of study, a blood sample was drawn from the children and PCV13 geometric mean 
antibody response were analyzed by a Luminex-based assay. Statistical analysis: Linear regression model, in R.
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pneumoniae serotypes8. In this study, we found that the antibody response to PCV13-vaccination was independ-
ent of the pneumococcal carrier status of the children.
Carrying a pneumococcal serotype is a prerequisite for developing IPD9. A study by Kimaro Mlacha et al. 
found that individuals respond with different dynamics following stimulation with pneumococcal polysaccharide 
antigens, and children aged 24–36 months with a history of IPD responded quicker than the healthy controls22. 
This may be due to a memory response elicited by the serotype that caused IPD23 or because the children may 
have been carrying pneumococcal serotypes beforehand. A study by Ingels et al. also showed the importance of 
evaluating pneumococcal antibody response on an individual level in children at higher risk of IPD24. The reason 
why we did not see a difference in PCV13 antibody response between carriers and non-carriers in our study may 
have several causes. Firstly, there might be individual differences in terms of responding time following PCV13 
vaccination. Secondly, the antibody responses might have been shaped by prior natural exposure to pneumococ-
cal antigens in nasopharyngeal carriage. Children who are exposed to pneumococci may be more likely to have 
acquired a wide repertoire of memory responses to different serotypes as proposed by Kimaro Mlacha et al.22. 
Thirdly, the antibody response to PCV13-included serotypes might not be affected by the antibody response to 
a non-vaccine serotype. However, we did see that the antibody response to some serotypes was affected by the 
carriage of other serotypes (supplementary figure 1), e.g. the antibody response to serotype 1 or 18 C were both 
higher in children carrying non-vaccine serotype 23 A than in children not carrying 23 A at baseline (before 
Figure 5. Being vaccinated against Hepatitis B increases the PCV13 antibody response at baseline but not at 
end of study in children that have followed the Danish basic vaccination program. At baseline and end of study, 
a blood sample was drawn from the children and the PCV13 geometric mean antibody responses were analyzed 
by a Luminex-based assay. The graph depicts the antibody response to PCV13 (Log10µg/mL) in children that 
have only followed the Danish basic vaccination program compared to children that along with the Danish 
basic vaccination program also have received Hepatitis B vaccination prior to either baseline or end of study 
(Baseline: Basic, n = 88; +HepB, n = 72; End of study: Basic, n = 75; +HepB, n = 85). Statistical analysis: Linear 
regression model in R.
Figure 6. At baseline, but not end of study, oral mucosal gene expressions of IL-8 and IL-1β are increased in 
children that are carriers of any serotype in the nose. At baseline and end of study, a nose and a cheek swab 
were taken from the children and the carrier status in nose was analyzed by serotyping, while oral mucosal gene 
expression was analyzed by qPCR. Graphs depict the fold change of oral mucosal gene expressions of (A) IL-8 
and (B) IL-1β at baseline and end of study in children that are either non-carriers or carriers of any serotype 
in the nose (Baseline: non-carrier, n = 190; carrier, n = 64. End of study: non-carrier, n = 83; carrier, n = 172), 
Statistical analysis: Linear regression model in R.
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entering day care), and the antibody response to 18 C was also higher in children carrying serotype 11 A com-
pared to children not carrying serotype 11 A at baseline. However, these analyses included few carriers of specific 
serotypes compared to non-carriers of that serotype and are therefore not reliable. Yet it cannot be excluded that 
colonization by one serotype may protect against colonization by another serotype, as competition-colonization 
between some pneumococcal serotypes have been reported25.
Our previous study10 showed a statistically significant difference between non-carriers and carriers in terms 
of living with or without siblings at baseline, showing a higher risk of carrying pneumococcal serotypes before 
day care attendance if the child has at least one older sibling. This study on the other hand shows that the PCV13 
antibody response was not affected by the number of siblings at baseline, but a higher PCV13 antibody response 
was seen in children with siblings at the end of study. Children at the end of the study received an extra dose of 
PCV13 compared to children at baseline. The number of siblings may affect the carriage status before day care 
attendance but not the PCV13 antibody response.
We found that vaccination against hepatitis B significantly increased the PCV13 antibody response at base-
line (p = 0.009) but not at the end of study (p = 0.468) in children who followed the Danish childhood vaccina-
tion program when adjusting for number of siblings as a potential risk factor for pneumococcal carriage. The 
non-significant finding at the end of the study might be because of day care attendance throughout 6 months, 
where the children were affected by several other external environmental factors such as more vaccinations and 
other microorganisms that cannot be accounted for in this study. However, early in life and prior to day care, 
the hepatitis B vaccine might affect the protection against pneumococcal serotypes by a bystander non-specific 
immune stimulation leading to an increase in the PCV13 antibody response. To our knowledge, the association 
between the PCV13 antibody response and the hepatitis B vaccine has not been described in other studies, but it 
could be considered whether to exploit this additive effect on PCV13 response along with additional hepatitis B 
protection in the Danish childhood vaccination program.
Our study shows an increase in the buccal mucosal gene expressions of IL8 and IL1B in children that are 
carriers of any pneumococcal serotype in the nasal cavity at baseline even when adjusting for number of siblings 
as a potential risk factor for carriage of S. pneumoniae. Other studies have found a higher expression of IL8 and 
IL1B in serum in hepatitis B virus (HBV) infected patients26–28, while another study found mainly IL-10 to be 
expressed in HBV infected patients and HBV-vaccinated individuals29. Mucosal expression of IL8 and/or IL1B 
indicates activation of the mucosal immune system, which is expected in the presence of bacteria30. We measured 
the expression of the cytokines in buccal swabs, while the carriage of pneumococci was determined from nose 
swabs. It is however expected that microorganisms found in the nose will be present in the mouth and throat as 
well, and vice versa. IL8 and IL1B play a crucial role in protection against both hepatitis B and S. pneumoniae, and 
our findings of an increase in PCV13 antibody response in children vaccinated against hepatitis B might be due 
to of an increased activation of the mucosal immune system. Our findings of an increased expression of IL8 and 
IL1B in pneumococcal carriers is supported by others30–32. Neutrophils are known to be critical in the protection 
against and the clearance of S. pneumoniae33,34 and are recruited to the site of colonization through IL8. Morris 
et al. (2017) found that the S. pneumoniae burden was significantly correlated with neutrophil recruitment and 
transcription of IL8 and that the transcription of IL8 in neutrophils was correlated with the secretion of IL8 into 
the nasopharynx30, while Marriott et al. (2012) showed that IL1B regulates IL8 release from epithelial cells in 
response to S. pneumoniae32. This might explain our finding of an increased gene expression of IL8 and IL1B in 
children carrying pneumococcal serotypes, however the oral cavity is highly polymicrobial and IL8 levels can 
be upregulated in response to the presence of other bacteria than S. pneumoniae as well. We see a correlation 
between buccal gene expressions of IL8 and IL1B and carriage of pneumococcal serotypes, yet we cannot exclude 
that other microorganisms affect this correlation.
In conclusion, the PCV13 antibody response was unaffected by whether the children were carriers or 
non-carriers of any pneumococcal serotype and entering day care equalized most effects of S. pneumoniae col-
onization measured before entering the day care. Children <2 years of age living with older siblings were more 
frequent carriers of pneumococcal serotypes before day care attendance, especially of the non-vaccine serotypes 
21 and 11 A, compared to children not living with siblings. Vaccination against hepatitis B increased the PCV13 
antibody response in children who followed the Danish childhood vaccination program before they entered day 
care. Lastly, we saw an increased mucosal gene expression of IL8 and IL1B in children carrying pneumococcal 
serotypes before day care attendance.
In the future, it is important to continue the surveillance of pneumococcal carriage and to monitor the effect 
of pneumococcal vaccination on carriage of non-vaccine serotypes. Further research is needed to investigate 
whether hepatitis B vaccination protects against pneumococcal carriage by increasing the PCV13 antibody 
response or by an increased gene expression of IL8 and IL1B. Lastly, further investigations are needed to examine 
whether the antibody response to one specific serotype is depended on the carriage of another serotype.
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